Abstract: Modular, miniaturized cardiovascular sensors, systems, methods, and wearable devices for the non-obtrusive evaluation, monitoring, and high-fidelity mapping of cardiac mechanical and electromechanical forces and central arterial blood pressure are presented herein. The sensor manufacturing process is also presented. Using accelerometers, the sensors register body-surface (preferably torso-surface) movements and vibrations generated by cardiac forces. The sensors may contain single-use or reusable components, which may be exchanged to fit different body sizes, shapes, and anatomical locations; they may be incorporated into clothing, bands, straps, and other wearable arrangements. The invention presents a practical, noninvasive solution for electromechanical mapping of the heart, which is useful for a wide range of healthcare applications, including the remote monitoring of heart failure status and the guidance of cardiac resynchronization therapy.

Abstract: A method for nucleic acid sequencing includes receiving a plurality of signals indicative of a parameter measured for a plurality of defined spaces, at least some of the defined spaces including one or more sample nucleic acids, the signals being responsive to a plurality of nucleotide flows introducing nucleotides to the defined spaces; determining, for at least some of the defined spaces, whether the defined space includes a sample nucleic acid; processing, for at least some of the defined spaces determined to include a sample nucleic acid, the received signals to improve a quality of the received signals; and predicting a plurality of nucleotide sequences corresponding to respective sample nucleic acids for the defined spaces based on the processed signals and the nucleotide flows.

Abstract: A portable system is provided for measuring a ketone, such as an acetone, in the breath or other bodily fluid of a user. The system includes a portable measurement device that analyzes fluid samples and generates corresponding ketone measurements. The portable measurement device communicates with an application which runs on a smartphone or other mobile device of the user. The application tracks, and generates graphs of, the ketone measurements, and may include various features for facilitating the analysis of the measurements. One such feature compares ketone measurements taken while the user is on a health program to a baseline level determined from pre-program-initiation ketone measurements.

Abstract: An apparatus 1 comprises a subject data obtaining unit 11 for obtaining subject data M4 of an inter-organ cross talk indicator in each organ other than a specific organ, a pattern similarity calculation unit 12 for calculating, by comparing the subject data M4 with standard data 1 of the inter-organ cross talk indicator, similarity of patterns of the inter-organ cross talk indicators, and a prediction unit 13 for predicting the presence of a specific disease and/or the stage of the specific disease by using the similarity as a measure.

Abstract: A device for searching a biomarker to be used for determining whether or not a first treatment has an effect on a disease, the biomarker search device includes: a first storage; a second storage storing; a third storage; a fourth storage; a signature molecular information detector; a regression analyzer; a network generator; and a biomarker determinator.

Abstract: A computing server generates a graph such as an identity-by-descent (IBD) network. The graph includes a plurality of nodes. Each node represents one of the individuals. Two or more nodes are connected through edges. Each edge connecting two nodes and associated with a weight that is derived from affinity between the genetic data of the two individuals represented by the two nodes. The computing system filters the graph based on features that are associated with the edges or the nodes. The filtered graph includes a subset of nodes. The computing system divides the filtered graph into a plurality of clusters to identify genetic communities that may not be discoverable without filtering. The computing server may also perform a multi-path hierarchical community detection process to assign an individual represented by a node to more than one communities.

Abstract: The present disclosure relates generally to the analysis of immune checkpoint proteins involved in cancer. In particular, the present disclosure provides material and methods for determining abundance ratios of various immune checkpoint proteins (e.g., PD-1, PD-L1, and PD-L2) present in a biospecimen sample based on quantification of peak area using mass spectrometry analysis. The methods disclosed herein provide an alternative platform for diagnosing and treating cancer, especially in cases limited by ineffective antibody recognition.

Abstract: Novel means that enables prediction of prognosis of a patient with cancer or inflammatory disease is disclosed. In the method for prediction of prognosis of a patient with cancer or inflammatory disease according to the present invention, the expression level of the FROUNT gene in a sample collected from the patient is measured. Since FROUNT is a poor prognostic factor, the lower the expression level of the FROUNT gene is, the better the prognosis in the patient is predicted to be. Or, the expression level of the CC chemokine receptor/ligand gene in a sample collected from the patient is measured. Since the CC chemokine receptor/ligand gene such as CCR2 or CCR5 is a good prognostic factor, the higher the expression level of the CC chemokine receptor/ligand gene is, the better the prognosis in the patient is predicted to be.

Abstract: Aspects of the present disclosure include systems for use in preparing a labelled biomolecule reagent. Systems according to certain embodiments include an input manager for receiving a request for a labelled biomolecule reagent, a memory for storing a dataset having a plurality of labelled biomolecule reagent storage identifiers, a processing module communicatively coupled to the memory and configured to identify one or more labelled biomolecule reagent storage identifiers from the dataset that corresponds to the labelled biomolecule reagent request and an output manager for providing the one or more identified labelled biomolecule reagent storage identifiers. A reagent preparatory apparatus for preparing the labelled biomolecule reagent from an activated biomolecule and activated label is also described. Methods for communicating and receiving a labelled biomolecule reagent request and preparing the subject labelled biomolecule reagents are also provided.

Abstract: Provided is an apparatus for estimating bio-information in a non-invasive manner. According to an exemplary embodiment, the bio-information estimation apparatus includes: a spectrum measurer configured to measure a spectrum of light reflected from an object; a temperature measurer configured to measure the temperature of the object while the spectrum measurer measures the spectrum of light reflected from the object; and a processor configured to calculate a spectrum correction factor, including one or more of a correction factor of a gain, a constant, and a slope, based on the measured temperature of the object, and to adjust the measured spectrum by using the calculated correction factor.

Abstract: Embodiments are related to the accurate detection of somatic mutations in the plasma (or other samples containing cell-free DNA) of cancer patients and for subjects being screened for cancer. The detection of these molecular markers would be useful for the screening, detection, monitoring, management, and prognostication of cancer patients. For example, a mutational load can be determined from the identified somatic mutations, and the mutational load can be used to screen for any or various types of cancers, where no prior knowledge about a tumor or possible cancer of the subject may be required. Embodiments can be useful for guiding the use of therapies (e.g. targeted therapy, immunotherapy, genome editing, surgery, chemotherapy, embolization therapy, anti-angiogenesis therapy) for cancers. Embodiments are also directed to identifying de novo mutations in a fetus by analyzing a maternal sample having cell-free DNA from the fetus.

Abstract: The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and/or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNF? inhibitor for the treatment of a TNF?-mediated disease or disorder.

Abstract: The present invention relates to a method for discovery of a novel miRNA biomarker for cancer diagnosis, a biomarker for diagnosis of bile duct cancer or pancreatic cancer which has been discovered through the method for discovery of a biomarker, a method for diagnosing cancer, comprising a step in which cancer is diagnosed when f(x)>0 by substitution of the expression level of the miRNA biomarker, which is detected by the method for discovery of a miRNA biomarker for cancer diagnosis, in a sample into a novel SVM classifier function, a kit for diagnosing bile duct cancer or pancreatic cancer comprising the biomarker for diagnosing bile duct cancer or pancreatic cancer, and a computing device for performing a process of diagnosing cancer when f(x)>0 as a result of a calculation by substitution of the expression level of a miRNA biomarker, which is detected by the method for discovery of a miRNA biomarker for cancer diagnosis, into the novel SVM classifier function.

Abstract: Disclosed are systems and methods for generating graphical displays of analyte data and/or health information. In some implementations, the graphical displays are generating based on a self-referential dataset that are modifiable based on identified portions of the data. The modified graphical displays can indicate features in the analyte data of a host.

Abstract: Disclosed are systems and methods for generating graphical displays of analyte data and/or health information. In some implementations, the graphical displays are generating based on a self-referential dataset that are modifiable based on identified portions of the data. The modified graphical displays can indicate features in the analyte data of a host.

Abstract: Aspects of the present disclosure provide systems, methods, and computer-readable storage media that leverage artificial intelligence and machine learning to screen candidate pharmaceutical molecules or compounds for pharmaceutical uses (e.g., treating diseases or conditions). The screening may be based on structural similarity between the candidate pharmaceutical molecules and various pharmaceutical targets (e.g., proteins, nucleic acids, etc.). In aspects, one or more machine learning (ML) models may be trained to assign a candidate pharmaceutical molecule to one of multiple clusters based on chemical/physical properties of the candidate pharmaceutical molecule and chemical/physical properties of pharmaceutical targets associated with the clusters. The pharmaceutical targets associated with the cluster may be scored based on comparisons between the candidate pharmaceutical molecule and the pharmaceutical target, and a subset of the pharmaceutical targets may be identified based on the scores.

Abstract: Provided are methods and apparatus for receiving sensor data from an analyte sensor of a sensor monitoring system, processing the received sensor data with time corresponding calibration data, outputting the processed sensor data, detecting one or more adverse conditions associated with the sensor monitoring system, disabling the output of the sensor data during the adverse condition time period, determining that the one or more detected adverse conditions is no longer present in the sensor monitoring system, retrieving the sensor data during the adverse condition time period, processing the retrieved sensor data during the adverse condition time period, and outputting the processed retrieved sensor data.

Abstract: The instant invention provides workflows for the design and characterization of mechanism-based sirtuin modulating compounds, including new or improved sirtuin activating compounds. Workflows for the design of mechanism-based sirtuin activating compounds are provided, based on conditions that must be satisfied by activators if they are to exploit the common catalytic mechanism of all sirtuin enzymes and hence increase catalytic efficiency for any sirtuin and any substrate.

Abstract: Systems, apparatuses, and methods as described herein relate to analyzing plant nutrient-yield relationships and identifying optimum plant fertilization strategies to improve individual plant yields and overall plant yields. Nutrient data and yield data for plants in all yield ranges, rather than nutrient data and yield data for only the best-performing plants, is categorized based on the yield data and then analyzed to determine the yield as a function of nutrient condition for each nutrient element for the plants in each yield category. The nutrient-yield function can be modeled using a polynomial equation of various orders that can be used for determining the nutritional condition to improve crop production for plants in each yield category.

Abstract: Disclosed herein is a system and method for increasing the fidelity of measured genetic data, for making allele calls, and for determining the state of aneuploidy, in one or a small set of cells, or from fragmentary DNA, where a limited quantity of genetic data is available. Poorly or incorrectly measured base pairs, missing alleles and missing regions are reconstructed using expected similarities between the target genome and the genome of genetically related individuals. In accordance with one embodiment, incomplete genetic data from an embryonic cell are reconstructed at a plurality of loci using the more complete genetic data from a larger sample of diploid cells from one or both parents, with or without haploid genetic data from one or both parents. In another embodiment, the chromosome copy number can be determined from the measured genetic data, with or without genetic information from one or both parents.